Overview

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

Status:
RECRUITING
Trial end date:
2031-04-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of AZD0486 administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies.
Phase:
PHASE1
Details
Lead Sponsor:
AstraZeneca
Treatments:
acalabrutinib
Cyclophosphamide
Doxorubicin
Prednisone
Rituximab
Vincristine